PDGFRA and chronic myelogenous leukemia, BCR-ABL1 positive: Of note, the “gate-keeper” mutant T674I FIP1L1-PDGFRα in HES, similar to T315I Bcr-Abl in CML, was also refractory to some second-generation TKIs, such as nilotinib, sorafenib [8].